JPMorgan lowered the firm’s price target on HealthEquity (HQY) to $123 from $129 and keeps an Overweight rating on the shares. The company reported a Q4 beat and fiscal 2027 guidance raise, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY: